David R. Spriggs

Harvard University US

0000-0003-2174-4992

425

Publications

17,389

Citations

H-Index

187

i10-Index

3.27

2yr Mean Cite

Cite/Paper

Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar

Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Detection of Circulating Tumor Necrosis Factor after Endotoxin Administration

H. R. Michie, Kirk R. Manogue, David R. Spriggs, Arthur Revhaug, Sarah O’Dwyer +4 more

New England Journal of Medicine 1988

1,707

Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

Martee L. Hensley, Robert G. Maki, Ennapadam Venkatraman, Gennifer Geller, Meghan Lovegren +5 more

Journal of Clinical Oncology 2002

685

Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. OA

Dennis E. Hallahan, David R. Spriggs, Michael A. Beckett, Donald Küfe, R.R. Weichselbaum

Proceedings of the National Academy of Sciences 1989

466

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

Carol Aghajanian, Steven L. Soignet, Don S. Dizon, Christine Pien, Julian Adams +8 more

PubMed 2002

456

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors <i>in vivo</i> OA

Mythili Koneru, Terence J. Purdon, David R. Spriggs, Susmith Koneru, Renier J. Brentjens

OncoImmunology 2015

409

Publications

425 total

Abstract 2884: Development of antibody drug conjugates targeting MUC16 in ovarian cancer subtypes

Mengyao Xu, Bo R. Rueda, David R. Spriggs, Yeku Oladapo - Cancer Research, 2025

Cited by 0 Semantic Scholar

Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers

Mengyao Xu, S. Barakzai, Raj Kumar, Irva E Veillard, Eugene Kim - Signal Transduction and Targeted Therapy, 2025

Cited by 1 Semantic Scholar

Abstract B086: Anchored in Resistance: Overcoming Nidogen-2 (NID2) - mediated Immunoresistance in Ovarian Cancer with Ras and Bcl-xl Inhibition

Fabian Kraus, Mengyao Xu, Raj Kumar, Irva E Veillard, William Manning - Molecular Cancer Therapeutics, 2025

Cited by 0 Semantic Scholar

Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma OA

Yusuke Matoba, Dominique T. Zarrella, Venkatesh Pooladanda, Maryam Azimi Mohammadabadi, Eugene Kim - British Journal of Cancer, 2024

Cited by 9 Semantic Scholar

Sialyl-Tn serves as a potential therapeutic target for ovarian cancer OA

Linah F. Al-Alem, Jillian Prendergast, Justin Clark, Bianca Zarrella, Dominique T. Zarrella - Journal of Ovarian Research, 2024

Cited by 13 Semantic Scholar

Abstract 7557: Hypoxia-induced downregulation of MUC16: A key player in bispecific T-cell engager resistance in ovarian cancer

Mengyao Xu, S. Barakzai, A.Yu. Kononenko, Raj Kumar, Irva E Veillard - Cancer Research, 2024

Cited by 0 Semantic Scholar

Correction: Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.

Songfa Zhang, Chuan Yan, D. Millar, Qiqi Yang, J. Heather - Cancer Research, 2024

Cited by 0 Semantic Scholar

Structural basis for antibody recognition of the proximal MUC16 ectodomain OA

Kwangkook Lee, K. Perry, Mengyao Xu, Irva E Veillard, Raj Kumar - Journal of Ovarian Research, 2024

Cited by 5 Semantic Scholar

Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma PDF

Yanxia Zhao, Jinghong Cao, Alexander Melamed, Michael J. Worley, Allison Gockley et al. - Proceedings of the National Academy of Sciences, 2019

Cited by 255 OpenAlex

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment PDF

Oladapo Yeku, Terence J. Purdon, Mythili Koneru, David R. Spriggs, Renier J. Brentjens - Scientific Reports, 2017

Cited by 389 OpenAlex

Research Topics

Ovarian cancer diagnosis and treatment (114) Monoclonal and Polyclonal Antibodies Research (52) Endometrial and Cervical Cancer Treatments (44) Immunotherapy and Immune Responses (40) Statistical Methods in Clinical Trials (38)

Frequent Co-Authors

Carol Aghajanian

5 joint publications

Martee L. Hensley

3 joint publications

Paul Sabbatini

3 joint publications

Mythili Koneru

3 joint publications

Renier J. Brentjens

3 joint publications

H. R. Michie

2 joint publications

Affiliations

Boston University

US 1987 - 1987

Northwestern University

US 2005 - 1996

University of Southern California

US 1996 - 1996

Gynecologic Oncology Group

US 2014 - 2004

Roche (Switzerland)

CH 2015 - 2015

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers

David R. Spriggs

Publication & Citation Trends

Most Cited Works

Publications

Abstract 2884: Development of antibody drug conjugates targeting MUC16 in ovarian cancer subtypes

Hypoxia induced VEGF secretion promotes resistance to bispecific T-cell engagers

Abstract B086: Anchored in Resistance: Overcoming Nidogen-2 (NID2) - mediated Immunoresistance in Ovarian Cancer with Ras and Bcl-xl Inhibition

Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma OA

Sialyl-Tn serves as a potential therapeutic target for ovarian cancer OA

Abstract 7557: Hypoxia-induced downregulation of MUC16: A key player in bispecific T-cell engager resistance in ovarian cancer

Correction: Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.

Structural basis for antibody recognition of the proximal MUC16 ectodomain OA

Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma PDF

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment PDF

Research Topics

Frequent Co-Authors

Affiliations

External Profiles

Share Profile

Journal Details

Join JournalsHub

Welcome Back